p-Cresol affects reactive oxygen species generation, cell cycle arrest, cytotoxicity and inflammation/atherosclerosis-related modulators production in endothelial cells and mononuclear cells

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Chang, Mei Chi ^a   Chang, Hsiao Hua ^b   Chan, Chiu Po ^c   Yeung, Sin Yuet ^c   Hsien, Hsiang Chi ^c   Lin, Bor Ru ^d   Yeh, Chien Yang ^b   Tseng, Wan Yu ^b   Tseng, Shui Kuan ^b   Jeng, Jiiang Huei ^b  

^a CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CRESOL; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROSTAGLANDIN F2 ALPHA; REACTIVE OXYGEN METABOLITE; TRYPAN BLUE; UROKINASE RECEPTOR; 4-CRESOL; UROKINASE;

APOPTOSIS; ARTICLE; ATHEROSCLEROSIS; CELL COUNT; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL GROWTH; CELL MEDIATED CYTOTOXICITY; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INFLAMMATION; MONONUCLEAR CELL; MTT ASSAY; PROTEIN ANALYSIS; PROTEIN SECRETION; S PHASE CELL CYCLE CHECKPOINT; BIOSYNTHESIS; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; METABOLISM; PATHOLOGY; SOLUBILITY; U937 CELL LINE;

APOPTOSIS; ATHEROSCLEROSIS; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CRESOLS; DINOPROST; ENDOTHELIAL CELLS; HUMANS; INFLAMMATION; LEUKOCYTES, MONONUCLEAR; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN SPECIES; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SOLUBILITY; U937 CELLS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84919341604     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114446     Document Type: Article

References (62)

1. Buckley JR (1904) The chemistry of pulp decomposition with rational treatment of this condition and its sequelae. J Am Dent Assoc 3: 764-771.
2. Myers DR, Kenneth H, Dirksen TR, Pashley DH, Whitford GM, et al. (1978) Distribution of 14C-formaldehyde after pulpotomy with formocresol. J Am Dent Assoc 96: 805-813.
3. Ranley DM, Garcia GF, Horn DA (1988) A comparison of the effects of cresol and eugenol on bovine pulp. Endod Dent Traumatol 4: 70-75.
4. Ohara P, Torabinejad M, Kettering JD (1993) Antibacterial effects of various endodontic medicaments on selected anaerobic bacteria. J Endod 19: 498-500.
5. Geypens B, Claus D, Evenepoel P, Hiele M, Maes B, et al. (1997) Influence of dietary protein supplements on the formation of bacterial metabolites in the colon. Gut 41: 70-76.
6. Curtius HC, Mettler M, Ettlinger L (1976) Study of the intestinal tyrosine metabolism using stable isotopes and gas chromatography-mass spectrometry. J Chromatogr 126: 569-580.
7. Dietz D (1991) NTP technical report on the toxicity studies of cresols in F344/N rats and B6C3F1 mice (Feed studies). Toxic Report Service 9: 1-128.
8. Sequeira DJ, Eyer CS, Cawley GF, Nick TG, Backes WL (1992) Ethylbenzene-mediated induction of cytochrome P450 isoenzymes in male and female rats. Biochem Pharmacol 44: 1171-1182.
9. Madyastha KM, Raj CP (1992) Metabolic date of methofuran in rats. Novel oxidative pathways. Drug Metab Dispos 20: 295-301.
10. Kamijo Y, Soma K, Kokuto M, Ohbu M, Fuke C, et al. (2003) Hepatocellular injury with hyperaminotransferasemia after cresol ingestion. Arch Pathol Lab Med 127: 364-366.
11. Vanholder R, De Smet R, Lesaffer G (1999) p-Cresol: a toxin revealing many neglected but relevant aspects of uraemic toxicity. Nephrol Dial Transplant 14: 2813-2815.
12. Meijers BK, Bammens B, De Moor B, Verbeke K, Vanrenterqhem Y, et al. (2008) Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 73: 1174-1180.
13. Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, et al. (2010) p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 5: 1182-1189.
14. Hosler GA, Cusumano AM, Hutchins GM (2003) Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Arch Pathol Lab Med 127: 834-839.
15. Chillon JM, Mozar A, Six I, Maizel J, Bugnicourt JM, et al. (2009) Pathophysiological mechanisms and consequences of cardiovascular calcifications: role of uremic toxicity. Ann Pharm Fr 67: 234-240.
16. Jono S, Shioi A, Ikari Y, Nichizawa Y (2006) Vascular calcification in chronic kidney disease. J Bone Miner Metab 24: 176-181.
17. Recht PA, Tepedino GJ, Siecke NW, Buckley MT, Mandeville JT, et al. (2004) Oxalic acid alters intracellular calcium in endothelial cells. Atherosclerosis 173: 321-328.
18. Ketteler M, Giachelli C (2006) Novel insights into vascular calcification. Kidney Int. (Suppl) 105: S5-9.
19. Glorieux G, Cohen G, Jankowski J, Vanholder R (2009) Platelet/leukocyte activation, inflammation and uremia. Semin Dial 22: 423-427.
20. Hirsh J, Genton E (1974) Thrombogenesis. In Physiological Pharmacology, pp 99-133. New York, Academic Press.
21. Westrick RJ, Eitzman DT (2007) Plasminogen activator inhibitor-1 in vascular thrombosis. Curr Drug Targets 8: 966-1002.
22. Enocsson H, Wettero J, Skogh T, Sjowall C (2013) Soluble urokinase plasminogen activator receptor levels reflect organ damage in systemic lupus erythromatosus. Transl Res 162: 287-296.
23. Merino A, Nogueras S, Buenda P, Ojeda R, Carracedo J, et al. (2008) Microinflammation and endothelial damage in hemodialysis. Contrib Nephrol 161: 83-88.
24. Kofler S, Nickel T, Weis M (2005) Role of cytokines in cardiovascular diseases: a focus on endothelial responses to inflammation. Clin Sci 108: 205-213.
25. Basu S (2010) Bioactive eicosanoids: role of prostaglandin F(2α) and F2-isoprostanes in inflammation and oxidative stress related pathology. Mol Cells 30: 383-391.
26. Malyszko J (2010) Mechanism of endothelial dysfunction in chronic kidney disease. Clin Chim Acta 411: 1412-1420.
27. Ochodnicky P, Vettoretti S, Henning RH, Buikema H, Van Dokkum RP, et al. (2006) Endothelial dysfunction in chronic kidney disease: determinant of susceptibility to end-organ damage and therapeutic response. J Nephrol 19: 246-258.
28. Ghiadoni L, Cupisti A, Huang Y, Mattei P, Carcinal H, et al. (2004) Endothelial dysfunction and oxidative stress in chronic renal failure. J Nephrol 17: 512-519.
29. Dou L, Cernini C, Brunet P, Guilianelli C, Maol V, et al. (2002) P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 62: 1999-2009.
30. Dou L, Bertrans E, Cerini C, Faure V, Sampol J, et al. (2004) The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 65: 442-451.
31. Wratten ML, Tetta C, De Smet R, Neri R, Sereni L, et al. (1999) Uremic ultrafiltrate inhibits plateletactivating factor synthesis. Blood Purif 17: 134-141.
32. Schepers E, Meert N, Glorieux G, Goeman J, Van der Eycken J, et al. (2007) P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 22: 592-596.
33. Faure V, Cerini C, Paul P, Berland Y, Dignat-George F, et al. (2006) The uremic solute p-cresol decreases leukocyte transendothelial migration in vitro. Int Immunol 18: 1453-1459.
34. Cerini C, Dou L, Anfosso F, Sabatier F, Moal V, et al. (2004) P-cresol, a uremic retention solute, alters the endothelial barrier function in vitro. Thromb Haemost 92: 140-150.
35. Shin WS, Szuba A, Rockson SG (2002) The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 160: 91-102.
36. Raghunath PN, Tomaszewski JE, Brady ST, Caron RJ, Okada SS, et al. (1995) Plasminogen activator system in human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 15: 1432-1443.
37. Filiopoulos V, Viassopoulos D (2009) Inflammatory syndrome in chronic kidney disease: pathogenesis and influence on outcomes. Inflamm Allergy Drug Targets 8: 369-382.
38. Himmelfarb J (2009) Uremic toxicity, oxidative stress and hemodialysis as renal replacement therapy. Semin Dial 22: 636-643.
39. Galle J, Seibold S, Wanner C (2003) Inflammation in uremic patients: what is the link? Kidney Blood Press Res 26: 65-75.
40. Tseng SK, Chang MC, Su CY, Chi LY, Hsu ML, et al. (2012) Arecoline induced cell cycle arrest, apoptosis and cell cycle arrest in human endothelial cells. Clin Oral Invest 16: 1267-1273.
41. Tseng SK, Chang MC, Hsu ML, Su CY, Chi LY, et al. (2014) Arecoline inhibits endothelial cell growth, migration and the attachment by mononuclear cells. J Dent Sci (In press).
42. Chang MC, Chen LI, Chan CP, Lee JJ, Wang TM, et al. (2010) The role of reactive oxygen species and hemeoxygenase-1 expression in the cytotoxicity, cell cycle alteration and apoptosis of dental pulp cells induced by BisGMA. Biomaterials 31: 8164-8171.
43. Chang MC, Uang BJ, Wu HL, Lee JJ, Hahn LJ, et al. (2002) Inducing the cell cycle arrest and apoptosis of oral KB carcinoma cells by hydroxychavicol: Roles of glutathione and reactive oxygen species. Br J Pharmacol 135: 619-630.
44. Chang MC, Wu HL, Lee JJ, Lee PH, Chang HH, et al. (2004) The induction of PGE2 production, IL-6 production, cell cycle arrest and apoptosis of primary oral keratinocytes and KB cancer cells by areca nut ingredients is differentially regulated by MEK/ERK. J Biol Chem 279: 50676-50683.
45. Chang HH, Guo MK, Kasten FH, Chang MC, Huang GF, et al. (2005) Stimulation of glutathione depletion, ROS production and cell cycle arrest of dental pulp cells and gingival epithelial cells by HEMA. Biomaterials 26: 745-753.
46. Ying Y, Yang K, Liu Y, Chen QJ, Shen WF, et al. (2011) A uremic solute, P-cresol, inhibits the proliferation of endothelial progenitor cells via the p38 pathway. Cir J 75: 2252-2259.
47. Gunthner T, Jankowski V, Kretschmer A, Nierhaus M, Van de Giet M, et al. (2009) Endothelium and vascular smooth muscle cells in the context of uremia. Semin Dial 22: 428-432.
48. Noh H, Yu MR, Kim HJ, Jang EJ, Hwang ES, et al. (2014) Uremic toxin p-cresol induces Akt-pathway-selective insulin resistance in bone marrow-derived mesenchymal stem cells. Stem Cells 32: 2443-2453.
49. Chang MC, Wang TM, Yeung SY, Jeng PY, Liao CH, et al. (2011) Antiplatelet effect of p-cresol, a uremic and environmental toxicant, is related to inhibition of reactive oxygen species, ERK/p38 signaling and thromboxane A2 production. Atherosclerosis 219: 559-565.
50. Zhu JZ, Zhang J, Yang K, Du R, Jing YJ, et al. (2012) P-cresol, but not p-cresylsulphate, disrupts endothelial progenitor cell function in vitro. Nephrol Dial Transplant 27: 4323-4330.
51. De Carvalho JT, Dalboni MA, Watanabe R, Peres AT, Goes MA, et al. (2011) Effect of spermidine and p-cresol on polymorphonuclear cell apoptosis and function. Artif Organs 35: E27-32.
52. Kawakami K, Makino I, Kato I, Uchida K, Onoue M (2009) P-cresol inhibits IL-12 production by murine macrophages stimulated with bacterial immunostimulant. Immunopharmacol Immunotoxicol 31: 304-309.
53. Vanholder R, De Smet R, Waterloos MA, Van Landschoot N, Vogeleere P, et al. (1995) Mechanisms of uremic inhibition of phagocyte reactive species production: characterization of the role of p-cresol. Kidney Int 47: 510-517.
54. Brunet P, Gondouin B, Duval-Sabatier A, Dou L, Cerini C, et al. (2011) Does uremia cause vascular dysfunction? Kidney Blood Press Res 34: 284-290.
55. Sahin G, Yalcin AU, Akcar N (2007) Effect of N-acetylcysteine on endothelial dysfunction in dialysis patients. Blood Purif 25: 309-315.
56. Yuhki K, Kashiwagi H, Kojima F, Kawabe J, Ushikubi F (2010) Roles of prostanoids in the pathogenesis of cardiovascular diseases. Int Angiol 29 (2 suppl): 19-27.
57. Xu Y, Hagege J, Mougenot B, Sraer JD, Ronne E, et al. (1996) Differential expression of the plasminogen activation system in renal thrombotic microangiopathy and the normal human kidney. Kidney Int 50: 2011-2019.
58. Bifulco K, Longanesi-Cattani I, Liguori E, Arra C, Rea D, et al. (2013) A urokinase receptor-derived peptide inhibiting VEGF-dependent directional migration and vascular sprouting. Mol Cancer Ther 12: 1981-1993.
59. Sloand EM, Pfannes L, Scheinberg P, More K, Wu CO, et al. (2008). Increased soluble urokinase plasminogen activator receptor (suPAR) is associated with thrombosis and inhibition of plasmin generation in paroxysmal nocturnal hemoglobinuria (PNH) patients. Exp Hematol 36: 1616-1624.
60. Eddy AA (2009) Serine proteases, inhibitors and receptors in renal fibrosis. Thromb Haemost 101: 656-664.
61. Edsfeldt A, Nitulescu M, Gratman H, Gronberg C, Persson A, et al. (2012) Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. Stroke 43: 3305-3312.
62. Zhang G, Eddy AA (2008) Urokinase and its receptors in chronic kidney disease. Front Biosci 13: 5462-5478.